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Abstract Deoxyguanosine kinase deficiency (dGK) is a
frequent cause of the hepatocerebral form of mitochondrial
depletion syndrome (MDS). A group of 28 infants with
severe progressive liver failure of unknown cause was
recruited for post mortem search for deoxyguanosine kinase
(DGUOK) gene mutations. Four affected patients (14% of
the studied group), two homozygotes, one compound
heterozygote, and one heterozygote, with DGUOK muta-
tion found on only one allele, were identified. Three known
pathogenic mutations in the DGUOK gene were detected,
c.3G>A (p.Met1Ile), c.494A>T (p.Glu165Val), and
c.766_767insGATT (p.Phe256X), and one novel molecular
variant of unknown pathogeneity, c.813_814insTTT (p.
Asn271_Thr272insPhe). Profound mitochondrial DNA
depletion was confirmed in available specimens of the liver
(4%, 15%, and 10% of the normal value) and in the muscle
(4%, 23%, 45%, and 6%, respectively). The patients were
born with low weights for gestational age and they
presented adaptation trouble during the first days of life.
Subsequently, liver failure developed, leading to death at
the ages of 18, 6, 5.5, and 2.25 months, respectively. Mild
neurological involvement was observed in all children
(hypotonia, psychomotor retardation, and ptosis). Hypogly-
cemia (hypoketotic) and lactic acidosis were the constant
laboratory findings. Elevated transferrin saturation, high
ferritin, and alpha-fetoprotein levels resembled, in two
cases, a neonatal hemochromatosis. Liver histopathology
showed severe hepatic damage ranging from micronodular
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DOI 10.1007/s13353-010-0008-yformation and cirrhosis to the total loss of liver architecture
with diffuse fibrosis and neocholangiolar proliferation. Pan-
creatic islet cell hyperplasia with numerous confluent giant
islets was found in both autopsied infants. Analysis of the
natural history of the disease in our patients and the literature
data led us to the following observations: (i) islet cell
hyperplasia (and hyperinsulinism) may contribute to MDS-
associated hypoglycemia; (ii) iron overload may additionally
damage mtDNA-depleted tissues; (iii) low birth weight,
adaptation trouble, and abnormal amino acids in newborn
screening are frequent in dGK-deficient neonates.
Keywords DGUOK gene mutation.mtDNA depletion.
Neonatal liver failure.Hypoglycemia.Iron overload.
Natural history of the disease
Hepatopathy is a prominent feature of mitochondrial
depletion syndrome (MDS) caused by mutations in the
nuclear genes encoding proteins responsible for mtDNA
maintenance, replication, or nucleotide substrate delivery
(POLG, DGUOK, and MPV17) (Dimmock et al. 2008).
Since 1991, an increasing number of MDS has been
reported among neonates, infants, and children who died
due to progressive liver failure (Müller-Höcker et al. 2002;
Rabinowitz et al. 2004). The disease is characterized by
tissue-specific pathology, generally unusual for mitochon-
drial disorders.
Deoxyguanosine kinase deficiency (dGK) associated
with mutations in the deoxyguanosine kinase (DGUOK)
gene was uncovered as a genetic background of hepatic
MDS phenotype by Mandel et al. in 2001 (Mandel et al.
2001). Since then, more than 50 patients from 35 affected
families have been reported (Salviati et al. 2002; Mancuso
et al. 2003; Filosto et al. 2004; Labarthe et al. 2005; Slama
et al. 2005; Wang et al. 2005; Freisinger et al. 2006; Sarzi et
al. 2007; Brahimi et al. 2009; Spinazzola et al. 2009). The
DGUOK gene mutations are considered to be the most
common genetic background of hepatic MDS, being
responsible for 14–20% of all mtDNA depletion cases
(Salviati et al. 2002). Mitochondrial involvement in dGK-
deficient patients is evidenced by lactic acidemia and
impaired function of the respiratory chain (Mandel et al.
2001). Normal complex II activity (encoded by the nuclear
genes) is a specific feature of MDS (Hargreaves et al.
2002).
Twenty-eight infants and children, who died due to
progressive liver failure, were recruited for post mortem
DGUOK gene mutations search. In all patients, a mito-
chondrial disease had been diagnosed before death. Two of
them were included in the COX deficiency cohort described
earlier (Böhm et al. 2006). The Bioethical Commission of
the Children’s Memorial Health Institute (CMHI) approved
the study protocol.
Total DNA, extracted from skeletal muscle and liver
samples, was used as a template to amplify seven coding
exons of the DGUOK gene. A set of primers corresponding
to each exon and splicing regions of DGUOK was used as
described previously (Mandel et al. 2001).
The polymerase chain reaction (PCR) conditions were as
follows: initial denaturation at 94°C for 2 min followed by
35 cycles at 94°C for 30 s, 62°C for 30 s, 72°C for 30 s,
and a final extension step at 72°C for 7 min. Single-
stranded DNA products were subjected to exonuclease I
digestion and shrimp alkaline phosphatase hydrolysis (Exo-
SAP-IT), according to the manufacturer’s protocol (USB
Corp.), and subsequently sequenced. Sequencing reaction
products were purified using DyeEx Kits prior to separation
on an ABI 3730 Genetic Analyzer. The gathered data were
analyzed using the Chromas Lite 2.01 software.
Sequence analysis revealed the presence of three known
pathogenic mutations, c.3G>A( p . M e t 1 I l e ) ,c . 4 9 4 A > G
(p.Glu165Val), and c.766_767insGATT (p.Phe256X), and
one new molecular variant of unknown pathogeneity,
c.813_814insTTT(p.Asn271_Thr272insPhe),intheDGUOK
gene. There were two homozygotes, one compound hetero-
zygote, and one affected patient with mutation found on only
one chromosome.
The most frequent mutation identified in our study was
the c.3G>A substitution in the DGUOK exon 1, potentially
causing a severe impairment in the synthesis of the protein.
It was found in two of our patients (in homozygous or
heterozygous status, respectively) and it was reported
previously only once, also in a patient of Polish origin
(Freisinger et al. 2006).
The second mutation, revealed on only one allele in this
study, was the frameshift 4-bp insertion in the DGUOK
exon 6 (c.766_767insGATT). Since 2002, it has been
reported in eight unrelated dGK-deficient patients from
different regions of the world, especially from Arabian
countries and Spain (Wang et al. 2005). The change is
considered to be the most frequent and it was suggested to
be either an ancient or a recurrent mutation (Salviati et al.
2002; Filosto et al. 2004; Labarthe et al. 2005).
The third known mutation located in exon 4 of the
DGUOK gene (c.494A>G) was found in our group in
homozygous form in a child of seemingly unrelated
parents. The change was reported in 2005 in one heterozy-
gous French patient (Slama et al. 2005; Poulton et al.
2009).
The fourth change was not reported previously
(c.813_814insTTT) and its pathogeneity requires further
confirmation. Profound mitochondrial DNA depletion
confirmed the diagnosis of MDS in this patient. The
depletion was also found in all available tissue specimens,
in the liver of the patients 1, 2, and 4 (4%, 15%, and 10%
of the normal value, respectively), and in all of the patients’
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et al. 2005;W ęglewska-Jurkiewicz 2009).
The course of the disease in our four dGK-deficient
patients resembled strikingly clinical features described in
the literature(Mandel etal. 2001; Slama et al. 2005;L a b a r t h e
et al. 2005; Freisinger et al. 2006). Since remarkable
difficulties in differential diagnosis were observed, an
expended metabolic testing was required. A number of
unusual or “strange” biochemical parameters (see Table 1)
directed investigations to various different metabolic path-
ways. More than ten genetic disorders (including tyrosinemia
neonatal or type I, homocystnuria, 2-CH3-3-hydroxybutyric
aciduria, galactosemia, hereditary fructose intolerance, cytru-
linemia type II, biotinidase deficiency, Wilson disease, and
lysosomal storage disorders) were suspected and subsequent-
ly excluded during the long-term hospitalizations in our
referral metabolic center. The diagnosis of a mitochondrial
disease was finally established in all four patients on the
basis of the association of the lactic acidosis, neurological
involvement (relatively mild), and cytochrome C oxidase
Table 1 Clinical characteristics and laboratory findings of the four patients with deoxyguanosine kinase (DGUOK) gene mutations
Patient Course of the disease; neurological
assessment
Specific biochemical abnormalities DNA change Protein change
Patient 1
girl
Two miscarriages. Low birth weight
(2,570 g); 1 d: hypoglycemia; 2 d:
hypotonia, vomiting, trembling; then:
hepatopathy, hypoglycemia; 15 mo:
progression of hepatic dysfunction
to end-stage liver failure and death
(18 mo)
NBS: ↑ methionine; 6 mo: GC-MS: ↑
2-CH3-3-OH-butyric acid,
3-methylglutaconic acid; slightly ↑
lactic acid, p-OH phenylpyruvic acid
derivatives; CDT slightly ↑ (14.0 %); ↑
CSF lactate; muscle biopsy: COX
deficiency
c.766_767insGATT/
c.?
p.Phe256X/
p.?
Neurological status: nystagmus,
generalized hypotonia, psychomotor
retardation
AFP 9700, 31000; Fe 55 TIBC 322
(sat 17%)
Patient 2
girl
Fetus hypotrophy (29 Hbd); caesarean
section due to fetus asphyxia (hbd 35,
1,859 g); 1 d: hypotonia, weakness,
feeding difficulties, vomiting; 4 d:
hepatopathy, hypoglycemia (26 mg/dl).
Since 2.5 mo: progression of liver
failure, ascites, severe coagulopathy,
cholestasis; died at the age of 6.5 mo
NBS: ↑ tyrosine; GC-MS: ↑ lactic acid,
p-OH phenylpyruvic acid derivatives; ↑
galactose excretion in urine; ↑ plasma
citrine; ↑ plasma lactate
c.3G>A/
c.813_814insTTT
p.Met1Ile/
Neurological status: hypotonia,
psychomotor retardation.
AFP 14500, 18500, 33500; Fe 25
TIBC 100 (sat 25%)
p.Asn271_
Thr272insPhe
Patient 3
girl
Low birth weight (2,640 g); 1 d: severe
hypoglycemia, hypotonia, tachypnoea,
hypothermia, hepatomegaly, metabolic
acidosis, hypertransaminasemia; 6 mo:
progression of liver failure, coagulopathy,
ascites; death
NBS: abnormal amino acids pattern. ↑
CK (586 – 207 iU) at neonatal period:
GC-MS: ↑↑ lactic acid; p-OH
phenylpyruvic acid derivatives ↓serum
ceruloplasmin (9 mg/dl) and Cu
(36 mg/dl); normal urinary Cu
excretion. Muscle biopsy: deficient
COX, low compl I
c.3G>A/c.3G>A p.Met1Ile/p.
Met1Ile
Neurological status: hypotonia,
psychomotor retardation
AFP 9700, 31000; ferritin 287, Fe 138
TIBC 184 (sat 75%)
Patient 4
boy
Low birth weight (2,350 g); 1 d:
generalized hypotonia, weakness,
hypoventilation, limbs edema,
hypoglycemia (10 mg/dl). Then:
progressive liver dysfunction
(cholestasis, jaundice, coagulopathy,
ascites); 10 wks: death due to end-
stage liver failure
Expended NBS ND; GC-MS: slightly ↑
lactic acid; p-OH phenylpyruvic acid
derivatives. Reducing substances in
urine – positive; ↑ homocysteine; ↓
serum biotinidase activity; ↑ plasma
and CSF lactate. Muscle biopsy:
deficient COX, low compl I
c.494A>T/c.494A>T p.Glu165Val/
p.Glu165Val
Neurological status: hypotonia,
psychomotor retardation
AFP 75000; ferritin 1146 Fe 121 TIBC
139 (sat 87%)
NBS, newborn screening; CK, creatine kinase; Cu, copper; CDT, carbohydrate-deficient transferrin (test for congenital glycosylation disorder);
GC-MS, gas chromatography–mass spectrometry method for assessment of the urinary profile of organic acids; COX, cytochrome C oxidase;
compl, complex of the respiratory chain; AFP, alpha-fetoprotein (normal < 5 IU); Fe, iron (normal 37–145 μg/dl); TIBC, total iron binding
capacity (normal 228–428 μg/dl); transferrin saturation normal value <30%; ferritin normal value 20–200 ng/dl; d, day(s); wks, weeks; mo,
months; CSF, cerebrospinal fluid; ND, not determined
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[OXPHOS] defect) found in the muscle biopsy (not shown).
Liver histopathology showed, generally, two distinct
patterns of damage. Patients 1 and 3 presented a similar model
of parenchymal injury accompanied by bridging fibrosis
leading to micronodular transformation and cirrhosis. This
picture suggested at least some drive for hepatocytic regener-
ation.Patients2and4showedtotallossoftheliverarchitecture
with diffuse fibrosis, neocholangiole proliferation, and no
tendency for cirrhotic nodular transformation, as was shown
earlier (Müller-Höcker et al. 2002; Mancuso et al. 2003;
Rabinowitz et al. 2004;L a b a r t h ee ta l .2005). Focal remnants
of the liver parenchyma were either necrotic or severely
changed, suggesting early profound hepatocyte injury with
subsequent domination of stromal and neocholangiolar
reaction. Pancreatic islet cell hyperplasia with numerous
confluent giant islets was found in both autopsied infants.
Generally, macro- and microscopic changes reported in the
dGK deficiency (Filosto et al. 2004) were not found in the
brain of our two autopsied patients. However, insufficient
material from accurately identifiable sites to exclude the
milder neuropathological features typical for mitochondrial
depletion syndromes was available.
A retrospective analysis of the clinical course of the
disease in our patients and the literature data led us to
summarize some important common observations. Firstly, a
relatively low birth weight (<10th percentile), intrauterine
growth retardation (IUGR), or prematurity was observed
not only in our dGK-deficient patients but was also
mentioned in 14 out of 19 values reported previously. The
detection of mtDNA depletion in one affected fetus
described additionally confirms a prenatal onset of the
disease (Müller-Höcker et al. 2002).
Secondly, our observations suggest, for the first time,
that an islet cell hyperplasia found at autopsy of two of
our patients may contribute to hypoglycemia in dGK
deficiency. Episodes of low glucose concentrations,
lasting from the disease onset to the end-stage period,
in all of our patients were observed. The hypoglycemia is
regularly reported in the hepatic form of MDS, including
dGK deficiency, but the impaired homeostasis back-
ground was not investigated. We clearly showed in our
two patients that it depends on a relative hyperinsulinism
(Fig. 1). The fasting test reveled the typical metabolic
profile of low ketone and beta-hydroxybutyrate (BOB)
production, relatively high insulin with lower free fatty
acids (FFA) release, and increase of hyperglycemic
hormones secretion (hGH, glucagon, cortisol) during
hypoglycemia. Brisk response to intravenous glucagon
injection (and the pancreatic autopsy findings mentioned
above) seems to confirm the hypothesis.
The influence of hypoglycemia on the severity of liver
dysfunction in the circumstances of mitochondrial energy
shortage in MDS may be especially important. Recently, an
improvement of the liver function on continuous intrave-
nous glucose infusions and regular feeding was reported in
the patients with MPV17 gene mutation (Parini et al. 2009).
Our patients received systematically glucose infusions also,
although the correlation between progression of the liver
failure and the current glucose supply status was not
possible to assess ex post.
Finally, some laboratory features of iron overload were
revealed in our affected patients (Siafakas et al. 1997;P o n k a
2002). Neonatal hemochromatosis was suspected initially in
two of the patients and it was excluded by the pathological
examination of the skin and the liver (not shown). However,
significant abnormalities in the iron metabolism and transport
were suggested by elevated transferrin saturation, relatively
low total iron binding capacity (TIBC), and/or increased
ferritin level (see Table 1). Theoretically, an excess of free
iron ions may have deleterious toxic influence on the liver
and subsequent organ damage (Visapää et al. 2002;R a m m
and Ruddell 2005). An impaired function of the mitochondria
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Fig. 1 Parameters of glucose homeostasis in two patients with deoxy-
guanosine kinase (DGUOK) gene mutations during fasting hypoglycemia
and after intravenous glucagon loading. BOB serum beta-hydroxybutyrate
(ketobutyrate) level; FFA serum free fatty acids level
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process. Decreased hepatic ATP content and reduced activity
of the cytochrome C oxidase was observed in an experimen-
tal model of iron overload (Bacon et al. 1993). In one report
describing a child with iron storage disease, a severe
depletion of mtDNA (to 9% of the normal value) was
mentioned (Vu et al. 2001).
Interestingly, in our cohort, serum alpha-fetoprotein (AFP)
elevation was constantly revealed (Table 1). On the dGK
discovery, Mandel et al. rated serum AFP increase as being
among the major biochemical findings (Mandel et al. 2001).
Only a few other reports mentioned AFP levels (Rabinowitz
et al. 2004), which ranged from <2 ng/ml in an affected
neonate to above 85,000 ng/ml or more in other reported
cases. The high serum AFP associated with liver malignancy
was described by Freisinger et al. in two dGK-deficient
patients (Freisinger et al. 2006). Hepatic carcinoma (HCC)
was not found in our patients by either liver ultrasound nor
during autopsy. It cannot be excluded that the mechanism of
the hyper-alpha-fetoproteinemia in dGK is connected with
the liver regeneration process (like in tyrosinemia type I),
and that, further, dGK-deficient patients will develop HCC if
they survive for longer without transplantation (Scheers et al.
2005; Freisinger et al. 2006).
In our experience, an early appropriate identification of
the mitochondrial pathology by the investigation of skeletal
muscle biopsy (apparently not impaired) may prevent
unnecessary escalation of the diagnostic procedures leading
to misdiagnoses and inadequate treatment.
A better understanding of the primary or secondary factors
influencing liver damage in MDS (including hypoglycemia
and iron overload) may contribute to the improvement of the
short- and long-term prognosis in children with the hepatic
form of this mitochondrial disorder.
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